RELATED PARTY TRANSACTIONS

6 Months Ended

Jun. 30, 2019

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS

NOTE 9—RELATED PARTY TRANSACTIONS

MSK is a shareholder of the Company and under the MSK License Agreement, the CD33 License Agreement, CTA, CFAs, SRA and MDSA, we have expensed costs in the total amount of $2,200,000 and $1,296,000 in the three months ended June 30, 2019 and 2018, respectively, for milestones, minimum royalties, and research and development costs. We expensed costs in the total amounts of $3,923,000 and $3,612,000 in the six months ended June 30, 2019 and 2018, respectively. Please refer to Note 6 for additional details on our various agreements with MSK. As of June 30, 2019 and December 31, 2018, we had a total of $4,596,000 and $4,475,000, respectively, recorded as accounts payable and accrued liabilities related to amounts due to MSK.